WO2019051327A3 - Agents de modulation des fonctions de la bêta-caténine et méthodes associées - Google Patents

Agents de modulation des fonctions de la bêta-caténine et méthodes associées Download PDF

Info

Publication number
WO2019051327A3
WO2019051327A3 PCT/US2018/050102 US2018050102W WO2019051327A3 WO 2019051327 A3 WO2019051327 A3 WO 2019051327A3 US 2018050102 W US2018050102 W US 2018050102W WO 2019051327 A3 WO2019051327 A3 WO 2019051327A3
Authority
WO
WIPO (PCT)
Prior art keywords
catenin
beta
methods
present disclosure
disclosure provides
Prior art date
Application number
PCT/US2018/050102
Other languages
English (en)
Other versions
WO2019051327A2 (fr
Inventor
Gerard HILINSKI
So Youn SHIM
Matthew Reiser PATTON
John Hanney MCGEE
Paula ORTET
Gregory L. Verdine
Original Assignee
Fog Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP18854947.1A priority Critical patent/EP3678683A4/fr
Priority to SG11202001162TA priority patent/SG11202001162TA/en
Priority to CA3074838A priority patent/CA3074838A1/fr
Priority to KR1020207009023A priority patent/KR20200064075A/ko
Application filed by Fog Pharmaceuticals, Inc. filed Critical Fog Pharmaceuticals, Inc.
Priority to EA202090513A priority patent/EA202090513A1/ru
Priority to MX2020002435A priority patent/MX2020002435A/es
Priority to JP2020536712A priority patent/JP2020533413A/ja
Priority to US16/645,407 priority patent/US11198713B2/en
Priority to CN201880057772.5A priority patent/CN111372942A/zh
Priority to AU2018329956A priority patent/AU2018329956A1/en
Priority to BR112020004555-1A priority patent/BR112020004555A2/pt
Publication of WO2019051327A2 publication Critical patent/WO2019051327A2/fr
Publication of WO2019051327A3 publication Critical patent/WO2019051327A3/fr
Priority to IL273015A priority patent/IL273015A/en
Priority to US17/518,247 priority patent/US11834482B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Abstract

La présente divulgation concerne entre autres des technologies de modulation des fonctions de la bêta-caténine. Dans certains modes de réalisation, la présente divulgation concerne des peptides agrafés qui interagissent avec la bêta-caténine. Dans d'autres, les peptides agrafés utilisés interagissent avec la bêta-caténine au niveau d'un site de liaison à l'axine de la bêta-caténine. Des composés, des compositions et des méthodes pour prévenir et/ou traiter des états pathologiques, des troubles et des maladies qui sont associés à la bêta-caténine sont en outre décrits.
PCT/US2018/050102 2017-09-07 2018-09-07 Agents de modulation des fonctions de la bêta-caténine et méthodes associées WO2019051327A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MX2020002435A MX2020002435A (es) 2017-09-07 2018-09-07 Agentes que modulan las funciones de beta-catenina y sus métodos.
CA3074838A CA3074838A1 (fr) 2017-09-07 2018-09-07 Agents de modulation des fonctions de la beta-catenine et methodes associees
KR1020207009023A KR20200064075A (ko) 2017-09-07 2018-09-07 베타-카테닌 기능을 조절하는 제제 및 이의 방법
US16/645,407 US11198713B2 (en) 2017-09-07 2018-09-07 Agents modulating beta-catenin functions and methods thereof
EA202090513A EA202090513A1 (ru) 2017-09-07 2018-09-07 Агенты, модулирующие функции бета-катенина, и связанные способы
SG11202001162TA SG11202001162TA (en) 2017-09-07 2018-09-07 Agents modulating beta-catenin functions and methods thereof
JP2020536712A JP2020533413A (ja) 2017-09-07 2018-09-07 ベータ−カテニンの機能を調節する薬剤及びその方法
EP18854947.1A EP3678683A4 (fr) 2017-09-07 2018-09-07 Agents de modulation des fonctions de la bêta-caténine et méthodes associées
CN201880057772.5A CN111372942A (zh) 2017-09-07 2018-09-07 调节β-联蛋白功能的物质及其方法
AU2018329956A AU2018329956A1 (en) 2017-09-07 2018-09-07 Agents modulating beta-catenin functions and methods thereof
BR112020004555-1A BR112020004555A2 (pt) 2017-09-07 2018-09-07 agentes que modulam funções de beta-catenina e métodos dos mesmos
IL273015A IL273015A (en) 2017-09-07 2020-03-03 Beta-catenin functional modulators and methods thereof
US17/518,247 US11834482B2 (en) 2017-09-07 2021-11-03 Agents modulating beta-catenin functions and methods thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555519P 2017-09-07 2017-09-07
US62/555,519 2017-09-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/645,407 A-371-Of-International US11198713B2 (en) 2017-09-07 2018-09-07 Agents modulating beta-catenin functions and methods thereof
US17/518,247 Continuation US11834482B2 (en) 2017-09-07 2021-11-03 Agents modulating beta-catenin functions and methods thereof

Publications (2)

Publication Number Publication Date
WO2019051327A2 WO2019051327A2 (fr) 2019-03-14
WO2019051327A3 true WO2019051327A3 (fr) 2019-04-18

Family

ID=65635271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/050102 WO2019051327A2 (fr) 2017-09-07 2018-09-07 Agents de modulation des fonctions de la bêta-caténine et méthodes associées

Country Status (14)

Country Link
US (2) US11198713B2 (fr)
EP (1) EP3678683A4 (fr)
JP (1) JP2020533413A (fr)
KR (1) KR20200064075A (fr)
CN (1) CN111372942A (fr)
AU (1) AU2018329956A1 (fr)
BR (1) BR112020004555A2 (fr)
CA (1) CA3074838A1 (fr)
EA (1) EA202090513A1 (fr)
IL (1) IL273015A (fr)
MA (1) MA50101A (fr)
MX (1) MX2020002435A (fr)
SG (1) SG11202001162TA (fr)
WO (1) WO2019051327A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001162TA (en) 2017-09-07 2020-03-30 Fog Pharmaceuticals Inc Agents modulating beta-catenin functions and methods thereof
EP3883588A4 (fr) 2018-11-21 2022-10-19 Endomet Biosciences, Inc. Compositions et méthodes pour traiter l'endométriose
US20220315631A1 (en) * 2019-08-30 2022-10-06 Ohio State Innovation Foundation Stapled beta-catenin ligands
IL299907A (en) * 2020-07-22 2023-03-01 Fog Pharmaceuticals Inc Paired peptides and their methods
WO2022261257A1 (fr) * 2021-06-08 2022-12-15 Fog Pharmaceuticals, Inc. Peptides agrafés et utilisations associées

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005118A1 (en) * 2010-09-22 2014-01-02 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US9056891B2 (en) * 2010-12-14 2015-06-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic peptide inhibitors of Wnt pathway
WO2017062518A1 (fr) * 2015-10-05 2017-04-13 Wntrx Pharmaceuticals Inc. Peptides bcl9 stabilisés pour le traitement de la signalisation wnt aberrante
WO2017147283A1 (fr) * 2016-02-23 2017-08-31 Dana-Farber Cancer Institute, Inc. Procédé de génération de peptides de pénétration cellulaire agrafés qui sont dépourvus de propriétés de lyse membranaire non spécifique pour le ciblage thérapeutique

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0360390A1 (fr) 1988-07-25 1990-03-28 Glaxo Group Limited Dérivés de spirolactames
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
EP1282722B1 (fr) 1999-10-15 2011-06-15 Avatar Medical, L.L.C. Proteines stabilisees
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US6822073B2 (en) 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
EP1648873A4 (fr) 2003-03-20 2008-06-25 Neuren Pharmaceuticals Ltd Composes macrocycliques neuroprotecteurs et procedes d'utilisation de ces composes
JP4778893B2 (ja) 2003-04-18 2011-09-21 エナンタ ファーマシューティカルズ インコーポレイテッド キノキサリニル大環状のｃ型肝炎セリンプロテアーゼ阻害剤
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
CA2544223C (fr) 2003-11-05 2017-03-07 Dana-Farber Cancer Institute, Inc. Peptides alpha-helicoidaux stabilises et leurs applications
EP1781324A2 (fr) 2004-08-20 2007-05-09 Novo Nordisk A/S Molecules pharmaceutiquement actives modulant le recepteur de l'insuline
AU2005274616A1 (en) 2004-08-20 2006-02-23 Phylogica Limited Peptide inhibitors of c-Jun dimerization and uses thereof
WO2006067091A1 (fr) 2004-12-20 2006-06-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Inhibiteurs d'homodimerisation de myd88
GB0511771D0 (en) 2005-06-09 2005-07-20 Novartis Ag Organic compounds
EP2091552A4 (fr) 2006-11-15 2010-01-06 Dana Farber Cancer Inst Inc Peptides maml stabilisés et leurs utilisations
EP2952522B1 (fr) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Peptides p53 stabilisés et leurs utilisations
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
JP5883220B2 (ja) 2007-05-02 2016-03-09 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 細胞のホメオスタシス経路および細胞の生存を調節する方法
WO2009020477A1 (fr) 2007-08-06 2009-02-12 Yale University Protéines miniatures modifiées
US8921323B2 (en) 2007-09-26 2014-12-30 Dana Farber Cancer Institute, Inc. Methods and compositions for modulating BCL-2 family polypeptides
AU2008308509B2 (en) 2007-10-04 2014-10-23 Zymogenetics, Inc. B7 family member zB7H6 and related compositions and methods
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
US20110144306A1 (en) 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
WO2010034034A1 (fr) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
US20110218155A1 (en) 2008-10-10 2011-09-08 Dana-Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
WO2010068684A2 (fr) 2008-12-09 2010-06-17 Dana Farber Cancer Institute, Inc. Procédés et compositions pour la modulation spécifique de mcl-1
EA021794B1 (ru) 2008-12-10 2015-09-30 Ачиллион Фармасьютикалз, Инк. Циклические аналоги 4-амино-4-оксобутаноил пептидов, ингибиторы репликации вирусов
DK2422201T3 (en) 2009-04-22 2015-05-18 Inst Medical W & E Hall STRUCTURE OF THE C-terminal region of the insulin receptor ALPHA CHAIN ​​AND THE INSULIN-LIKE GROWTH FACTOR RECEPTOR ALPHA CHAIN
WO2010132869A2 (fr) 2009-05-15 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Ligands mimétiques de peptide de domaine de boîte polo de kinase 1 de type polo et procédés d'utilisation
WO2010148335A2 (fr) 2009-06-18 2010-12-23 Dana Farber Cancer Institute, Inc. Compositions de peptides viraux structurés et procédés d'utilisation
DE102009032902A1 (de) 2009-07-10 2011-01-13 Forschungsverbund Berlin E.V. Induktion von α-Helix-Konformationen in Proteinen und Peptiden
CN102510755A (zh) * 2009-07-13 2012-06-20 哈佛大学校长及研究员协会 双功能钉接多肽和其用途
EP3138838A1 (fr) 2010-01-29 2017-03-08 Dana-Farber Cancer Institute, Inc. Petites molécules pour la modulation de mcl-1 et procédés de modulation de la mort cellulaire, la division cellulaire, la différenciation cellulaire et procédés de traitement de troubles
US8748570B2 (en) 2010-05-25 2014-06-10 Syngene Limited Insulin analogues
CA2804618C (fr) 2010-07-09 2020-09-08 Dana-Faber Cancer Institute, Inc. Peptides insulinotropes stabilises et procedes d'utilisation
CA2817568A1 (fr) 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Therapies et diagnostics du cancer
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
CN108276490B (zh) * 2011-04-15 2022-07-05 达纳-法伯癌症研究所有限公司 使用BCL-9的安定的α螺旋将癌症中失调WNT信号传递订为目标
EP2721061A4 (fr) 2011-06-17 2014-11-05 Harvard College Peptides maml variants stabilisés et leurs utilisations
WO2012174423A1 (fr) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Polypeptides stabilisés comme régulateurs de fonction gtpase rab
WO2013055949A2 (fr) 2011-10-11 2013-04-18 Dana Farber Cancer Institute, Inc. Pyrazol-3-ones qui activent le bax pro-apoptotique
US10077290B2 (en) 2011-12-29 2018-09-18 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
AU2013235425B2 (en) 2012-03-20 2017-09-21 Dana Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
EP2901154B1 (fr) 2012-09-25 2018-11-21 The Walter and Eliza Hall Institute of Medical Research Structure d'insuline dans un complexe avec des régions terminales en n et en c de la chaîne alpha du récepteur de l'insuline
JP6506166B2 (ja) 2012-09-26 2019-04-24 プレジデント アンド フェローズ オブ ハーバード カレッジ プロリンロックドステープルドペプチドおよびその用途
WO2014055564A1 (fr) 2012-10-01 2014-04-10 President And Fellows Of Harvard College Modulateurs stabilisés du récepteur de l'insuline polypeptidique
WO2014110420A1 (fr) 2013-01-10 2014-07-17 Noliva Therapeutics Llc Composés peptidomimétiques
WO2014159969A1 (fr) 2013-03-13 2014-10-02 President And Fellows Of Harvard College Polypeptides à agrafes et à suture et leurs utilisations
US10308926B2 (en) 2013-03-15 2019-06-04 Dana-Farber Cancer Institute, Inc. Stablized EZH2 peptides
WO2014144768A2 (fr) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Peptides bh4 stabilisés et leurs utilisations
WO2014144148A1 (fr) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Peptides sos1 stabilisés
WO2014197821A1 (fr) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Protéines de fusion à homéodomaine et leurs utilisations
EP3008081B1 (fr) 2013-06-14 2017-08-30 President and Fellows of Harvard College Modulateurs stabilisés du récepteur de l'insuline polypeptidique
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
AU2015264122B2 (en) 2014-05-21 2021-02-04 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
JP2018511594A (ja) 2015-03-18 2018-04-26 マサチューセッツ インスティテュート オブ テクノロジー 選択的ｍｃｌ−１結合ペプチド
CN108026146A (zh) 2015-07-02 2018-05-11 达纳-法伯癌症研究所股份有限公司 稳定的抗微生物肽
WO2017040329A2 (fr) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides se liant à bfl -1
WO2017040323A2 (fr) 2015-08-28 2017-03-09 Dana-Farber Cancer Institute, Inc. Peptides stabilisés permettant une liaison covalente avec une protéine cible
SG11202001162TA (en) 2017-09-07 2020-03-30 Fog Pharmaceuticals Inc Agents modulating beta-catenin functions and methods thereof
CN113039195A (zh) * 2018-08-20 2021-06-25 弗格制药有限公司 肽集合、肽试剂及其使用方法
CA3159729A1 (fr) 2019-12-11 2021-06-17 Amrita Singh CHANDHOKE Technologies utiles pour evaluer la permeabilite
US20230357320A1 (en) 2020-03-17 2023-11-09 Fog Pharmaceuticals, Inc. Helical stapled peptides and uses thereof
CN116113621A (zh) 2020-07-22 2023-05-12 弗格制药有限公司 氨基酸
IL299907A (en) 2020-07-22 2023-03-01 Fog Pharmaceuticals Inc Paired peptides and their methods
WO2022261257A1 (fr) 2021-06-08 2022-12-15 Fog Pharmaceuticals, Inc. Peptides agrafés et utilisations associées

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005118A1 (en) * 2010-09-22 2014-01-02 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US9056891B2 (en) * 2010-12-14 2015-06-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic peptide inhibitors of Wnt pathway
WO2017062518A1 (fr) * 2015-10-05 2017-04-13 Wntrx Pharmaceuticals Inc. Peptides bcl9 stabilisés pour le traitement de la signalisation wnt aberrante
WO2017147283A1 (fr) * 2016-02-23 2017-08-31 Dana-Farber Cancer Institute, Inc. Procédé de génération de peptides de pénétration cellulaire agrafés qui sont dépourvus de propriétés de lyse membranaire non spécifique pour le ciblage thérapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GROSSMANN, TN ET AL.: "Inhibition of oncogenic Wnt signaling through direct targeting of [beta]-catenin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 109, no. 44, 30 October 2012 (2012-10-30), pages 17942 - 17947, XP055089903 *

Also Published As

Publication number Publication date
AU2018329956A1 (en) 2020-08-20
KR20200064075A (ko) 2020-06-05
EP3678683A4 (fr) 2021-07-14
US11198713B2 (en) 2021-12-14
EP3678683A2 (fr) 2020-07-15
JP2020533413A (ja) 2020-11-19
CA3074838A1 (fr) 2019-03-14
EA202090513A1 (ru) 2020-08-24
MX2020002435A (es) 2020-09-22
US20220213154A1 (en) 2022-07-07
BR112020004555A2 (pt) 2020-09-24
CN111372942A (zh) 2020-07-03
IL273015A (en) 2020-04-30
US11834482B2 (en) 2023-12-05
SG11202001162TA (en) 2020-03-30
MA50101A (fr) 2020-07-15
WO2019051327A2 (fr) 2019-03-14
US20200247858A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
AU2018338314A1 (en) Protein degraders and uses thereof
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
PH12020550523A1 (en) Modulators of the integrated stress pathway
WO2019051327A3 (fr) Agents de modulation des fonctions de la bêta-caténine et méthodes associées
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
AU2017261336A1 (en) Modulators of the integrated stress pathway
AU2017260367A1 (en) Modulators of the integrated stress pathway
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
WO2018109170A3 (fr) Anticorps il-11ra
AU2017260374A1 (en) Modulators of the integrated stress pathway
AU2018258581A8 (en) RAF-degrading conjugate compounds
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
EP4112611A3 (fr) Modulateurs d'interaction sestrine-gator2 et leurs utilisations
WO2016100619A3 (fr) Traitement et diagnostic du cancer
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
WO2017035430A3 (fr) Anticorps anti-alk et leurs procédés d'utilisation
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18854947

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3074838

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020536712

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020004555

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018854947

Country of ref document: EP

Effective date: 20200407

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18854947

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2018329956

Country of ref document: AU

Date of ref document: 20180907

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112020004555

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200306